189 related articles for article (PubMed ID: 14551138)
21. 17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Anticancer Res; 2015 Oct; 35(10):5453-60. PubMed ID: 26408708
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells.
Villa R; Folini M; Porta CD; Valentini A; Pennati M; Daidone MG; Zaffaroni N
Carcinogenesis; 2003 May; 24(5):851-9. PubMed ID: 12771028
[TBL] [Abstract][Full Text] [Related]
23. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.
Bonvini P; Dalla Rosa H; Vignes N; Rosolen A
Cancer Res; 2004 May; 64(9):3256-64. PubMed ID: 15126367
[TBL] [Abstract][Full Text] [Related]
24. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
Münster PN; Basso A; Solit D; Norton L; Rosen N
Clin Cancer Res; 2001 Aug; 7(8):2228-36. PubMed ID: 11489796
[TBL] [Abstract][Full Text] [Related]
25. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
Sanderson S; Valenti M; Gowan S; Patterson L; Ahmad Z; Workman P; Eccles SA
Mol Cancer Ther; 2006 Mar; 5(3):522-32. PubMed ID: 16546966
[TBL] [Abstract][Full Text] [Related]
26. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
Burger AM; Fiebig HH; Stinson SF; Sausville EA
Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
[TBL] [Abstract][Full Text] [Related]
27. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
Yao Q; Nishiuchi R; Kitamura T; Kersey JH
Leukemia; 2005 Sep; 19(9):1605-12. PubMed ID: 16034464
[TBL] [Abstract][Full Text] [Related]
28. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
[TBL] [Abstract][Full Text] [Related]
29. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
[TBL] [Abstract][Full Text] [Related]
30. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
[TBL] [Abstract][Full Text] [Related]
31. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene.
Sundström M; Vliagoftis H; Karlberg P; Butterfield JH; Nilsson K; Metcalfe DD; Nilsson G
Immunology; 2003 Jan; 108(1):89-97. PubMed ID: 12519307
[TBL] [Abstract][Full Text] [Related]
32. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
33. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases.
Nimmanapalli R; O'Bryan E; Kuhn D; Yamaguchi H; Wang HG; Bhalla KN
Blood; 2003 Jul; 102(1):269-75. PubMed ID: 12623837
[TBL] [Abstract][Full Text] [Related]
34. CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.
Bandara G; Falduto GH; Luker A; Bai Y; Pfeiffer A; Lack J; Metcalfe DD; Olivera A
Front Immunol; 2023; 14():1078958. PubMed ID: 37025992
[TBL] [Abstract][Full Text] [Related]
35. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
Nimmanapalli R; O'Bryan E; Bhalla K
Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726
[TBL] [Abstract][Full Text] [Related]
36. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
39. In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.
Ochel HJ; Gademann G
Anticancer Res; 2006; 26(3A):2085-91. PubMed ID: 16827149
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P
Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
